Estudios clínicos con inhibidores de la PCSK9

Proprotein convertase subtilisin kexin 9 enzyme inhibitors are a novel therapeutic tool for the select group of very high risk patients who have not achieved LDL cholesterol goals. They have proven to have a powerful hypolipidemic effect and a good safety profile. Their use is expected to benefit patients by reducing their cardiovascular risk.